Generation Bio Future Growth
Future criteria checks 0/6
Generation Bio's revenue is forecast to decline at 15.6% per annum while its annual earnings are expected to grow at 11.5% per year. EPS is expected to grow by 24.1% per annum. Return on equity is forecast to be -19% in 3 years.
Key information
11.5%
Earnings growth rate
24.1%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | -15.6% |
| Future return on equity | -19.0% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -80 | N/A | N/A | 5 |
| 12/31/2025 | 7 | -81 | -75 | -71 | 7 |
| 12/31/2024 | 18 | -118 | -53 | -48 | 7 |
| 9/30/2024 | 19 | -145 | -104 | -98 | N/A |
| 6/30/2024 | 13 | -158 | -110 | -103 | N/A |
| 3/31/2024 | 10 | -169 | -65 | -57 | N/A |
| 12/31/2023 | 6 | -127 | -60 | -53 | N/A |
| 9/30/2023 | 3 | -124 | -54 | -51 | N/A |
| 6/30/2023 | 1 | -127 | -50 | -46 | N/A |
| 3/31/2023 | N/A | -134 | -101 | -95 | N/A |
| 12/31/2022 | N/A | -137 | -111 | -102 | N/A |
| 9/30/2022 | N/A | -135 | -111 | -100 | N/A |
| 6/30/2022 | N/A | -136 | -114 | -102 | N/A |
| 3/31/2022 | N/A | -129 | -112 | -104 | N/A |
| 12/31/2021 | N/A | -119 | -98 | -92 | N/A |
| 9/30/2021 | N/A | -112 | -94 | -89 | N/A |
| 6/30/2021 | N/A | -101 | -91 | -85 | N/A |
| 3/31/2021 | N/A | -88 | -80 | -75 | N/A |
| 12/31/2020 | N/A | -81 | -76 | -70 | N/A |
| 9/30/2020 | N/A | -72 | -68 | -64 | N/A |
| 6/30/2020 | N/A | -68 | -66 | -57 | N/A |
| 3/31/2020 | N/A | -65 | -62 | -46 | N/A |
| 12/31/2019 | N/A | -61 | -60 | -40 | N/A |
| 12/31/2018 | 0 | -36 | -31 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GBIO's revenue is expected to decline over the next 3 years (-15.6% per year).
High Growth Revenue: GBIO's revenue is forecast to decline over the next 3 years (-15.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBIO is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 01:00 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Generation Bio Co. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Eun Kyung Yang | Jefferies LLC |
| Farzin Haque | Jefferies LLC |